// Filing Digest — factual summary, not investment analysis

Merck Initiates Phase I Trial for Cyprumed Oral Peptide Technology, Triggering Up to $493M Payment

Sep 29

Merck & Co Inc (MRK) has announced the initiation of a Phase I clinical trial for Cyprumed's oral peptide tablet technology. The trial marks the first human clinical development for the technology.

The company stated that the initiation of the trial triggers a milestone payment from Merck to Cyprumed. The total value of this payment is up to $493 million.

The article, published by Benzinga on September 29, 2026, reports on the development of the oral peptide tablet technology and the associated financial milestone.

Source: the original filing or story →

Steve Ysreal Monas

Editor-in-Chief and Publisher

Monas Financial is published by Steve Ysreal Monas. He is an author of business, self-help, and fiction books — including The Lean Startup Blueprint and The Resilience Chronicles — and is based in Hawaii.

stevemonas.com → Amazon Author Page →